Effect of valproic acid on the pharmacokinetic profile of oxcarbazepine in the rat

Pharmaceutica Acta Helvetiae

Volumn 73, Issue 5, 1999, Pages 247-250

  Matar, K M ^a   Nicholls, P J ^b   Bawazir, S A ^a   Al Hassan, M I ^a   Tekle, A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Oxcarbazepine; Pharmacokinetic interaction; Rat; Valproic acid

Indexed keywords

OXCARBAZEPINE; VALPROIC ACID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; DRUG INTERACTIONS; MALE; RATS; RATS, SPRAGUE-DAWLEY; VALPROIC ACID;

EID: 0033032527     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6865(98)00030-2     Document Type: Article

References (10)

1. Eadie M. Formation of active metabolites of anticonvulsant drugs; a review of their pharmacokinetic and therapeutic significance. Clin. Pharmacokinet. 21:1991;27-41.
2. Faigle J., Menge G. Metabolic characteristics of oxcarbazepine (Trileptal®) and their beneficial implications for enzyme induction and drug interactions. Behav. Neurol. 3:1990;21-30. Suppl. 1.
3. Ketter T., Post R., Worthington K. Principles of clinically important drug interactions with carbamazepine: Part 1. J. Clin. Psychopharmacol. 11:1991;198-203.
4. Lloyd P., Flesch G., Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia. 35:1994;S10-S13. Suppl. 3.
5. Matar K.M., Nicholls P.J., Al-Hassan M.I., Tekle A. Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high performance liquid chromatography. J. Clin. Pharm. Ther. 20:1995;229-234.
6. Rembeck B., May T., Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Ther. Drug. Monit. 9:1987;298-303.
7. Riva R., Albani F., Contin M., Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs; clinical considerations. Clin. Pharmacokinet. 31:1996;470-493.
8. Robbins D., Wedlund P., Kuhri R., Baumann R., Levy R., Chang S. Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine. Br. J. Clin. Pharmacol. 29:1990;759-762.
9. Tartara A., Galimberti C.A., Manni R., Morini R., Limido G., Gatti G., Bartoli A. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in health subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br. J. Clin. Pharmacol. 36:1993;366-368.
10. Wagner J., Schmid K. Induction of microsomal enzymes in rat liver by oxcarbazepine, 10,11-dihydro-10-hydroxy-carbamazepine and carbamazepine. Xenobiotica. 17:1987;951-956.